*Last updated: October 11, 2026. PrimeTime BioLabs editorial team.*
On August 24, 2026, the FDA signed warning letters to five online peptide sellers. The agency posted them publicly a week later, on September 1. One letter told Royal Peptides that despite its research-use statements, website evidence "establishes that your products are intended to be drugs for human use." That sentence is the clearest statement US regulators have made about what a research-use label does and does not do.
This guide covers what the label means legally, what the FDA changed in 2026, where individual peptides stand today, and what happens next. The thesis runs through all of it. Research use only describes how a product may lawfully be sold. It is not permission for human use.
---
Start here if you just want the short answer
1. What does "research use only" actually mean?
Research use only is a labeling statement. It tells buyers that a seller offers a compound for laboratory work rather than for people. The phrase describes the conditions under which a product may lawfully be sold. It grants no permission to the person who buys it, and the FDA judges sellers by their whole presentation rather than the disclaimer.
2. Can you legally buy research peptides in the United States?
Federal enforcement targets sellers, not individual buyers. The FDA acts against companies marketing unapproved new drugs, which is a charge about marketing and intent. Buying a compound labeled for research does not place you outside that framework, but you are not who the agency writes letters to.
3. Did anything become legal in 2026?
No, nothing became legal in 2026. The FDA moved several peptides between administrative categories and an advisory committee made recommendations. Neither of those actions changed the law. Compounding these substances still requires rulemaking that has not happened.
Legal information, not legal advice. This page explains publicly available federal regulatory materials. It does not cover your situation, and it is not a substitute for a lawyer.
---
What "research use only" actually means in law
The FDA does not evaluate a disclaimer on its own. Under what regulators call intended-use doctrine, the agency reads everything a seller communicates. Product pages, marketing copy, social posts, and even what ships alongside a vial all count as evidence.
Five companies learned how that works in August. The letters went to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations, trading as Tex Peptides. FDA reviewers had examined each website in July 2026. Every letter cited unapproved new drug violations, and every one addressed the research-use labeling directly.
Enforcement did not stop with those five. FDA sent a further warning letter to Empower Pharmacy on September 18, 2026.
One finding deserves particular attention from anyone running a storefront. The FDA pointed to Peptide Partners selling a reconstitution solution next to injectable products. The agency treated that as giving buyers the means to prepare an injectable for human administration. Supplies sold on the same page became evidence of intent. A compliant catalog and a non-compliant one can contain the same molecules and differ only in what sits beside them.
A second federal body reached the same conclusion through a different route. Operation Supplement Safety, the Department of Defense program covering supplement risks for service members, states plainly that BPC-157 is an unapproved drug. OPSS also notes that such products often carry research-chemical or research-use labels. The program tells service members to avoid them whatever the route. Two agencies with separate mandates now treat the label as describing the seller rather than protecting the buyer.
Anyone evaluating where a product came from should read our supplier guide, which covers how to assess a seller's documentation and sourcing claims.
---
How we got here, from 2023 to 2027
Most coverage compresses four years into a headline about peptides becoming legal. The record is more specific than that, and the distinctions decide what is actually permitted.
Date | What happened | What it changed legally | Source |
|---|---|---|---|
Sep 29, 2023 | FDA added BPC-157, KPV, Melanotan II, ibutamoren mesylate and others to 503A Category 2 | Blocked 503A compounding of those substances | FDA, *Certain Bulk Drug Substances... May Present Significant Safety Risks* |
Apr 15, 2026 | FDA announced the removal of 12 peptides from Category 2 | Announcement only, nothing in force yet | FDA 503A categories document |
Apr 16, 2026 | Federal Register notice at 91 FR 20465, docket FDA-2025-N-6895 | Set the July PCAC meeting and opened a public docket, closed Jul 22. Carried no removals | Federal Register |
Apr 22, 2026 | Removals took effect. GHK-Cu left Category 1 the same day | Lifted the Category 2 flag without granting Category 1 status | FDA 503A categories document |
May 5, 2026 | A nominator clarified it had withdrawn only injectable GHK-Cu | Non-injectable GHK-Cu returning to Category 1 | FDA 503A categories document |
Jul 23-24, 2026 | PCAC reviewed seven peptide families, split into 14 voting questions, and recommended six | Nonbinding recommendation. No legal change | Federal Register notice and meeting reporting |
Aug 24 / Sep 1, 2026 | Five warning letters signed, then posted | Enforcement action rejecting research-use labeling | FDA warning letters |
Sep 18, 2026 | Warning letter to Empower Pharmacy | Enforcement continuing past the five | FDA warning letters |
Before end of Feb 2027 | PCAC to be consulted on GHK-Cu | Not yet scheduled. No docket published | FDA 503A categories document |
Three details in that table correct claims you will find almost everywhere else.
The April removals did not follow a safety review. FDA's own document states the nominations were withdrawn by the nominators. Nobody at the agency concluded these peptides were safe. The paperwork supporting their evaluation simply went away, so the category entry went away with it.
April 15 and April 22 are different events, and sources that merge them produce wrong answers. The first date is when FDA announced its intent. The second is when the change took effect.
The Federal Register notice did not carry the removals. Docket FDA-2025-N-6895 announced a meeting and opened a comment period. Several widely cited articles claim this notice set a seven-day effective date for the Category 2 changes. It did not, and the removals came through FDA's own categories document instead.
As for the July vote, its margins matter as much as its outcome. FDA's scientific reviewers opposed all seven peptides, citing thin clinical data and characterization problems. The committee voted against its own agency's reviewers. Emideltide failed 6 to 7 with one abstention, and epitalon passed 7 to 4 with one abstention. FDA published no official tallies, so those counts come from law-firm and trade-press accounts of the meeting. Recommendations from an advisory committee bind nobody.
---
Where each major peptide stands right now
Before the table, one misconception needs clearing up, because it drives a lot of search traffic and almost every answer to it is wrong. People look for the FDA peptide ban list. No such list exists. The FDA does not ban peptides as a category, and no document anywhere names prohibited peptides. What exists is a three-part administrative system for bulk drug substances nominated for compounding under section 503A. Category 1 covers substances under evaluation that may be eligible. Category 2 covers substances FDA has flagged for significant safety risks. Category 3 covers nominations submitted without adequate support. Asking which peptides are banned produces a confused answer because the question assumes machinery that was never built.
Here is what FDA's live categories document shows.
Substance | Current 503A status | What that allows |
|---|---|---|
BPC-157, TB-500, Semax, Epitalon, KPV, MOTS-c | In neither Category 1 nor Category 2 | No compounding pathway. Removal from Category 2 did not grant eligibility |
Ibutamoren mesylate | Category 2 | Still flagged. Never left |
Kisspeptin-10 | Category 2 | Still flagged. Never left |
GHK-Cu, non-injectable | Returning to Category 1 | Under evaluation, pending PCAC review |
GHK-Cu, injectable | Out of Category 2, awaiting PCAC | No compounding pathway |
Vasoactive Intestinal Peptide | Category 1 | Under evaluation and potentially eligible |
GHRP-2, GHRP-6, Mechano growth factor, Cibinetide | Category 3 | Nominated without adequate support |
Two rows in that table contradict the common framing. Ibutamoren mesylate and kisspeptin-10 sit in Category 2 today, which means reporting that describes peptides as having come off the restricted list is inaccurate. Category 2 still holds six substances in total.
The six headline peptides occupy an odd space that explains most confusion about their status. They appear in no category at all. Leaving Category 2 removed a warning flag, and Category 1 is what actually signals possible eligibility for the 503A bulks list. Falling between the two grants nothing.
One caution on reading that table, which reports 503A status only. Several of these substances appear separately on 503B lists at a different status. A figure quoted without its section number can look like a contradiction.
GHK-Cu took the strangest path of any substance here. Its non-injectable form left Category 1 on April 22 because the nominations were withdrawn. Two weeks later a nominator said it had meant to withdraw only the injectable route, so the topical form is being restored to Category 1. Both forms are headed for PCAC consultation before the end of February 2027.
---
Why GLP-1 drugs and research peptides are not on the same track
Searchers routinely treat semaglutide and BPC-157 as the same legal question. Legally they are nowhere near the same question.
Approved GLP-1 medications went through the full drug approval process. A clinician writes a prescription, a pharmacy dispenses it, and the product carries an FDA-approved label. Everything about that transaction is settled law.
Research peptides have no approved label, because no sponsor completed an approval for them. A missing label changes what a clinician can lawfully do. A peptide cannot be prescribed off-label when no approved label exists in the first place, which is a distinction many clinic marketing pages get wrong.
The August letters named compounds from both groups, and that is worth understanding correctly. FDA cited semaglutide, tirzepatide and retatrutide next to SS-31, PT-141 and tesamorelin. The common thread was marketing unapproved products as drugs for human use, not any shared regulatory status.
Four words get used interchangeably in this space and mean entirely different things. Approval means FDA cleared a drug for a specific use. Listing means a substance appears on a compounding bulks list. A committee recommendation means an advisory panel suggested something nonbinding. A ban means a prohibition, which, as covered above, does not describe how peptides are handled at all.
---
Does your state have its own peptide rules
Every state starts from the same federal baseline. States add their own layer through pharmacy boards, medical boards and consumer protection law, and enforcement varies more than the statutes do.
Tier | What it looks like | Notes |
|---|---|---|
Permissive | No peptide-specific statute, enforcement follows federal action | Most states sit here |
Moderate | No specific statute, but active board oversight of compounding and telehealth | Enforcement tends to follow federal developments |
Restrictive | Strong consumer protection authority and active board enforcement | California, New York and Connecticut are commonly placed here |
California deserves a direct answer because people search for it specifically. We found no California statute targeting peptides as a category and no confirmed California attorney general enforcement action against a peptide seller. California follows federal law, with oversight running through the Board of Pharmacy, the Medical Board, and general consumer protection authority. Anyone making decisions based on state law should verify locally, since this is a bounded finding rather than a guarantee.
Military readers face a clearer and stricter answer. BPC-157 appears on the DoD Prohibited Dietary Supplement Ingredients List under DoDI 6130.06, and it sits in WADA class S0 for non-approved substances. OPSS advises service members to avoid prohibited research chemicals whatever the route. For anyone subject to military testing, the July advisory vote changed nothing.
State boards act on their own authority and their own timelines. A federal category change does not automatically alter what a state board will do, in either direction.
---
What the law actually goes after when someone sells peptides
The target is marketing, not molecules. Federal law does not prohibit the existence of BPC-157. It prohibits selling an unapproved new drug, and a product becomes a drug through intended use.
Selling to genuine research institutions differs from selling to individuals. A laboratory buying a reference compound for bench work sits in one position. A storefront whose copy describes effects on appetite, recovery or sleep sits in another. Once a page explains effects on the body, it has supplied evidence of intended use.
Three practices show up repeatedly in enforcement. Describing physiological effects alongside a research disclaimer. Selling preparation supplies next to the compound. Using testimonials or imagery that depict human use. Each one contributes to the same finding.
People searching whether peptides are legal to buy online usually want a different answer than the one that exists. Websites selling these compounds are not themselves unlawful. FDA looks instead at how a storefront presents what it sells. Two sites offering the same vial can sit on opposite sides of the line.
Analytical testing sits outside this question entirely. A certificate of analysis speaks to identity, purity and quantity by a stated method. It says nothing about legal status, and nothing about whether a compound is safe or effective in people. Our COA guide covers how to read one and what its limits are.
---
The bottom line
Peptide law in 2026 moved a great deal administratively and not at all legislatively. Categories shifted because nominations were withdrawn. A committee recommended six substances without binding anyone. Enforcement continued throughout, and the five August letters made clear that research-use labeling does not survive marketing that describes effects on the body.
What the record does not show is worth stating plainly. We do not know when or whether FDA will propose a rule. We cannot predict the February 2027 outcome, since the session has not been scheduled or docketed. State enforcement varies and our state findings are bounded rather than comprehensive.
Not legal advice. This page summarizes public regulatory documents for general information. It does not address your circumstances and creates no attorney-client relationship. Consult qualified counsel before making decisions about purchasing, selling, or handling these compounds.
